CARCINOMA, OVARIAN EPITHELIAL
Clinical trials for CARCINOMA, OVARIAN EPITHELIAL explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, OVARIAN EPITHELIAL trials appear
Sign up with your email to follow new studies for CARCINOMA, OVARIAN EPITHELIAL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for tough cancers
Disease control OngoingThis early-stage study tests a new drug called KFA115, alone or with pembrolizumab, in people with advanced cancers like lung, skin, kidney, and others. The main goal is to find the safest dose and understand side effects. About 126 participants will be enrolled to see if the tre…
Matched conditions: CARCINOMA, OVARIAN EPITHELIAL
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 07:24 UTC
-
New drug combo shows promise in preventing ovarian cancer relapse
Disease control OngoingThis study looks at whether adding olaparib to standard bevacizumab treatment can help keep advanced ovarian cancer from coming back. About 190 women with a specific genetic marker (HRD-positive) will receive this combination as maintenance therapy after initial chemotherapy. The…
Matched conditions: CARCINOMA, OVARIAN EPITHELIAL
Phase: PHASE4 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated May 17, 2026 07:23 UTC
-
New drug combo could slow ovarian Cancer's return
Disease control OngoingThis study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian cancer live longer without their cancer growing. About 615 newly diagnosed patients who had surgery to remove most of their cancer will receive either …
Matched conditions: CARCINOMA, OVARIAN EPITHELIAL
Phase: PHASE3 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated May 17, 2026 07:22 UTC
-
Ovarian cancer trial tests immune booster against resistant tumors
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (with or without bevacizumab) can slow the growth of ovarian cancer that has stopped responding to platinum-based treatments. About 643 adults with recurrent ovarian, fallopian tube, or …
Matched conditions: CARCINOMA, OVARIAN EPITHELIAL
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 04, 2026 16:30 UTC